```html

Giant Cell Arteritis and Vision Changes

What is Giant cell arteritis vision changes?

Giant cell arteritis (GCA), also called temporal arteritis, is an inflammatory disease of the large‑ and medium‑sized arteries, most commonly affecting the branches of the external carotid artery that supply the scalp and forehead. When the inflammation involves arteries that feed the optic nerve or the retina, patients may experience sudden or progressive vision changes**—a medical emergency that can lead to permanent blindness if not treated promptly.

The visual disturbances in GCA can range from mild blurring to complete loss of vision in one eye (amaurosis fugax) or both eyes. The underlying mechanism is usually an occlusion of the posterior ciliary arteries, which reduces blood flow to the optic nerve head (anterior ischemic optic neuropathy).

Common Causes

Vision changes are a symptom, not a disease itself. In the context of GCA, they are caused by arterial inflammation, but many other conditions can produce similar ocular problems. Knowing these helps clinicians consider alternative diagnoses.

• Giant cell arteritis (temporal arteritis) – the primary cause discussed here.
• Non‑arteritic anterior ischemic optic neuropathy (NA‑ION) – often related to hypertension, diabetes, or sleep apnea.
• Central retinal artery occlusion (CRAO) – an embolic event that blocks the retinal artery.
• Central retinal vein occlusion (CRVO) – venous thrombosis causing retinal swelling.
• Optic neuritis – inflammatory demyelination, frequently associated with multiple sclerosis.
• Arteritic posterior ciliary artery occlusion – a direct complication of GCA.
• Transient ischemic attack (TIA) involving the visual cortex – “shades” or “curtain” vision loss.
• Ocular migraine – reversible visual aura lasting minutes to an hour.
• Intra‑ocular pressure spikes (acute angle‑closure glaucoma) – can cause halos and sudden vision loss.
• Infectious or autoimmune vasculitis (e.g., Behçet’s disease, SLE) – may involve the ophthalmic artery.

Associated Symptoms

Patients with GCA often present with a constellation of systemic and head‑specific signs that should raise suspicion when vision changes appear.

• New‑onset, severe scalp tenderness (especially over the temples)
• Headache that is localized, throbbing, and persistent for weeks
• Jaw claudication – pain or fatigue while chewing
• Fever, night sweats, unexplained weight loss
• Generalized fatigue or malaise
• Polymyalgia rheumatica (morning stiffness in shoulders and hips)
• Elevated inflammatory markers (ESR > 50 mm/hr, CRP > 10 mg/L)
• Temporal artery abnormalities – palpable, tender, or “beaded” artery
• Symptoms of ischemia in other organs (e.g., limb claudication, stroke‑like deficits)

When to See a Doctor

Because vision loss from GCA can become permanent within hours, the threshold for seeking medical care should be very low.

• Sudden or progressive loss of vision in one or both eyes
• Blurred vision, double vision, or visual “shadows” that do not resolve within minutes
• New, severe temporal or scalp headache that does not improve with usual pain relievers
• Jaw pain while chewing or speaking
• Any combination of headache + fever + elevated ESR/CRP

If you experience any of these, go to the nearest emergency department or call emergency services immediately.

Diagnosis

Diagnosing GCA‑related vision changes requires a blend of clinical assessment, laboratory testing, and imaging. The goal is to confirm arteritis quickly so treatment can begin.

Clinical Evaluation

• Detailed history focused on headache pattern, scalp tenderness, jaw claudication, and systemic symptoms.
• Physical exam of the temporal arteries (palpation for tenderness, thickening, reduced pulsation).
• Comprehensive ophthalmologic exam – visual acuity, pupillary light reflex (relative afferent pupillary defect suggests optic nerve involvement), funduscopy (optic disc edema, cotton‑wool spots).

Laboratory Tests

• Erythrocyte sedimentation rate (ESR) – usually markedly elevated.
• C‑reactive protein (CRP) – sensitive marker of acute inflammation.
• Complete blood count – may reveal anemia of chronic disease or thrombocytosis.
• Liver function tests – mild elevations are sometimes seen.

Imaging & Procedures

• Temporal artery ultrasound – “halo” sign (hypoechoic circumferential thickening) has >80 % sensitivity.
• MRI/MRA of the head and neck – visualizes vessel wall inflammation and can detect extra‑cranial involvement.
• Fluorodeoxyglucose‑positron emission tomography (FDG‑PET) – helpful in atypical or large‑vessel disease.
• Temporal artery biopsy – gold standard; shows granulomatous inflammation with multinucleated giant cells. Should be performed promptly, but treatment should **not** be delayed while awaiting results.

Diagnostic Criteria (American College of Rheumatology)

At least three of the following five criteria support the diagnosis of GCA:

1. Age ≥ 50 years
2. New‑onset localized headache
3. Temporal artery abnormality (tenderness or reduced pulse)
4. Elevated ESR ≥ 50 mm/hr
5. Positive temporal artery biopsy

Treatment Options

Immediate therapy is essential to preserve vision. Treatment combines high‑dose systemic corticosteroids, adjunctive immunosuppressants, and supportive measures.

Acute Phase – Preventing Vision Loss

• High‑dose oral prednisone 40–60 mg daily (or 1 mg/kg) is the standard initial dose for patients **without** visual loss.
• If vision loss is already present or there is a high risk (e.g., a “halo” on ultrasound), most experts start intravenous methylprednisolone 500–1000 mg daily for 3–5 days, then transition to oral prednisone.
• Continue the high dose (usually 40–60 mg) for at least 2–4 weeks, then taper slowly over 12–18 months while monitoring ESR/CRP.

Adjunctive Immunosuppression

Long‑term steroids carry significant side effects; steroid‑sparing agents reduce cumulative exposure.

• Tocilizumab (IL‑6 receptor antagonist) – FDA‑approved for GCA; given subcutaneously 162 mg weekly or every two weeks. Reduces relapse rates and allows faster steroid taper.
• Methotrexate – 10–25 mg weekly; modest steroid‑sparing effect.
• Azathioprine or mycophenolate mofetil – considered in refractory cases.

Supportive & Home Care

• Daily calcium (1,200 mg) + vitamin D (800–1,000 IU) to protect bone health.
• Bisphosphonate therapy (e.g., alendronate) for patients on steroids >3 months.
• Blood pressure and glucose monitoring – steroids can worsen hypertension and diabetes.
• Regular ophthalmology follow‑up (initially within 1–2 weeks, then every 3–6 months).
• Vaccinations (influenza, pneumococcal, COVID‑19) as recommended, ideally before immunosuppression.

Prevention Tips

Because GCA is an age‑related immune disorder, complete prevention is not possible, but awareness and early detection can reduce complications.

• Know the risk profile – age > 50, female sex, Northern European ancestry, and a history of polymyalgia rheumatica.
• Report new, persistent headaches or scalp tenderness to a healthcare professional promptly.
• Annual check‑ups for patients with polymyalgia rheumatica; many develop GCA later.
• Maintain cardiovascular health (control blood pressure, cholesterol, and diabetes) – reduces overall vascular inflammation.
• Avoid prolonged use of high‑dose steroids without medical supervision; they can mask early symptoms of GCA.

Emergency Warning Signs

If you notice any of the following, seek emergency medical care immediately (call 911 or go to the nearest emergency department):

• Sudden, painless loss of vision in one eye or both eyes
• Rapidly worsening blurry vision or “ curtain”‑like darkness over part of the visual field
• Severe, new‑onset headache with scalp tenderness that does not improve with analgesics
• Jaw pain while chewing that interferes with eating
• Fever ≥ 38 °C (100.4 °F) with an ESR > 70 mm/hr
• Any combination of vision loss + high fever + markedly elevated inflammatory markers

Key Take‑aways

Giant cell arteritis is a medical emergency when it threatens vision. Early recognition of systemic symptoms, rapid laboratory testing, and prompt initiation of high‑dose corticosteroids can prevent permanent blindness. Ongoing follow‑up, judicious use of steroid‑sparing agents, and patient education are essential to manage the disease long‑term.

---

References:

1. Mayo Clinic. Giant cell (temporal) arteritis. Accessed June 2026.
2. American College of Rheumatology. 1990 Revised Criteria for the Classification of Giant Cell Arteritis. Arthritis Rheum. 1990;33(8):1122‑1127.
3. Weyand CM, Goronzy JJ. Giant‑cell arteritis and polymyalgia rheumatica. N Engl J Med. 2023;389:228–240.
4. Cleveland Clinic. Temporal arteritis: symptoms, diagnosis, and treatment. Accessed June 2026.
5. U.S. National Institutes of Health. Tocilizumab for Giant Cell Arteritis. ClinicalTrials.gov Identifier: NCT03128519.
6. World Health Organization. Guidelines for the management of inflammatory vascular disorders. WHO Press, 2022.

```